Pelvic Angiography in Non-Responders to Phosphodiesterase-5 Inhibitors (PANPI) (PANPI)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00574184 |
Recruitment Status :
Completed
First Posted : December 17, 2007
Last Update Posted : October 31, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Erectile Dysfunction |
Study Type : | Observational |
Actual Enrollment : | 10 participants |
Observational Model: | Cohort |
Time Perspective: | Cross-Sectional |
Official Title: | Pelvic Angiography in Non-Responders to Phosphodiesterase-5 Inhibitors (PANPI) |
Study Start Date : | August 2005 |
Actual Primary Completion Date : | March 2008 |
Actual Study Completion Date : | March 2008 |

- Distal aortography with iliofemoral run-off will be performed to evaluate disease in the common and internal iliac arteries. [ Time Frame: During Procedural Cath ]
- Selective angiography of the internal pudendal artery (and accessory pudendal artery if present) will be performed bilaterally. [ Time Frame: During Procedural Cath ]
- Intra-arterial nitroglycerin (or papaverine or tolazoline if nitroglycerin is contraindicated) will be used to facilitate angiographic visualization of the internal pudendal and penile arteries. [ Time Frame: During Procedural Cath ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Male patients
- at least 50 years
- erectile dysfunction
- dissatisfaction with their use of a phosphodiesterase-5 inhibitor
- coronary artery disease (or at risk for coronary artery disease)
- undergoing diagnostic cardiac catheterization or patients with peripheral vascular disease undergoing peripheral arteriography
Exclusion Criteria:
- Patients who respond favorably to phosphodiesterase-5 inhibitors
- known non-vascular etiologies of their erectile dysfunction
- probable neurogenic erectile dysfunction due to radiation injury, surgery, or transurethral resection of the prostate
- calculated GFR < 60 ml/min/1.73 m2 will also be excluded
- disease that necessitates complex percutaneous intervention will be excluded per the investigators discretion

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00574184
Principal Investigator: | Jason Rogers, MD | University of California, Davis |
Responsible Party: | University of California, Davis |
ClinicalTrials.gov Identifier: | NCT00574184 |
Other Study ID Numbers: |
200513528 |
First Posted: | December 17, 2007 Key Record Dates |
Last Update Posted: | October 31, 2017 |
Last Verified: | March 2008 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
ED Erectile Dysfunction |
Erectile Dysfunction Sexual Dysfunction, Physiological Sexual Dysfunctions, Psychological Mental Disorders |